All articles tagged with #mounjaro
Eli Lilly’s sponsorship of Vogue World: Milano has triggered sharp criticism from health experts and charities, who argue the partnership normalizes medical weight loss as a beauty standard. While the event featured plus-size models, critics contend the association between a major pharmaceutical brand and high fashion reinforces harmful thinness ideals.
An AI analysis of around 400,000 Reddit posts uncovers signals of potentially under-reported or overlooked side effects linked to GLP-1 drugs Ozempic and Mounjaro, suggesting new safety signals that warrant clinical validation and heightened pharmacovigilance.
The View co-host Ana Navarro revealed on the show that she’s been taking the GLP-1 drug Mounjaro, which she says contributed to a drastic weight loss alongside a total lifestyle overhaul that includes healthier eating, more activity, and working with a nutritionist and medical supervisor after learning she’s pre-diabetic. Navarro had previously denied using Ozempic in 2023. She also noted a Mexico wellness spa trip with friends as part of adopting healthier habits, and cautioned that weight management is a daily, personal struggle without universal solutions. The report also recalls that other The View hosts have discussed GLP-1 use in the past.
A new study shows retatrutide, an experimental triple-hormone weight‑loss jab, delivering about 22% body-weight loss in roughly 48 weeks—outperforming Mounjaro's ~19% over ~17 months; GLP-1 drugs like Wegovy and Ozempic hover around 18% in similar timeframes, while retatrutide remains unapproved by the MHRA in the UK. The analysis draws on 38 trials with more than 25,000 participants.
Insurers are shrinking GLP-1 weight-loss coverage ahead of 2027, but Eli Lilly just gained a concrete tool to defend diabetes reimbursement: the FDA expanded Mounjaro’s label to show cardiovascular risk reduction in high-risk adults with type 2 diabetes. The obesity coverage pullback remains, and payers are unlikely to be swayed by obesity claims, though the label provides medical-necessity language that could narrow exposure—especially with Medicare’s $50/month Bridge Program. Lilly’s growth remains strong (Q2 revenue up 91% to nearly $10B, full-year guidance raised), but the market hasn’t priced a full coverage shield into the stock yet.
The FDA broadened Mounjaro’s use to lower major cardiovascular events in high‑risk adults with type 2 diabetes, with Lilly citing an additional 8% reduction versus Trulicity; the same drug is sold as Zepbound for weight loss, and Lilly is pursuing newer hormone‑targeting therapies.
The FDA approved Eli Lilly’s diabetes drug Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in high‑risk adults with Type 2 diabetes, based on a trial showing an 8% lower rate of cardiovascular death, heart attack or stroke compared with Trulicity; Mounjaro is also marketed for weight loss as Zepbound. The piece highlights the growing GLP‑1 drug pipeline, including next‑generation therapies like retatrutide, and notes payer coverage trends that favor use for diabetes or cardiovascular risk reduction over obesity treatment.
BBC follows comedian Steffen Peddie’s personal use of weight-loss injections (Wegovy) to shed over 8 stone and examines why men discuss such treatments less openly than women. With about 1.6 million adults in England, Wales and Scotland estimated to have used weight-loss drugs in 2024–25 (often bought privately), the piece shares men’s experiences, the stigma and privacy surrounding use, reported side effects, and medical calls for open discussion and routine monitoring to ensure safe, effective use.
A 19-year-old law student from Corona, California, died in a London dorm after taking tirzepatide, a widely prescribed GLP-1/GIP weight‑loss drug sold as Mounjaro and Zepbound. An inquest found her death was due to cardiac arrhythmia, with doctors noting a congenital heart condition (myocardial bridging) that may have contributed; vomiting could have triggered electrolyte imbalances leading to the arrhythmia. Nasr had been prescribed Zepbound by a U.S. doctor and was not obese, highlighting potential risks associated with GLP-1 therapies.
An observational study of about 53,000 people with type 2 diabetes and established heart disease found tirzepatide (Mounjaro) was associated with a 33% lower risk of major cardiovascular events, including heart attack, over roughly one year compared with sitagliptin; 2.9% vs 4.4% event rates, roughly one event prevented per 70 new tirzepatide users. The findings add to evidence GLP-1 meds may support heart health, but the study’s observational design and short follow-up limit conclusions, and tirzepatide is not FDA-approved for cardiac risk reduction.
Eli Lilly beat estimates again, lifted full-year guidance, and extended its lead in the GLP-1 obesity/diabetes market with strong demand for Mounjaro and Zepbound, sending the stock higher. Novo Nordisk also beat and raised guidance but faced investor skepticism over its growth trajectory after Wegovy missed expectations, mixed results for its experimental CagriSema, and concerns about pipeline diversification. The market remains bifurcated: Lilly is seen as the momentum winner, while Novo grapples with turning around its growth story despite European expansion and Wegovy's continued rollout, including a September German launch.
Eli Lilly beat Q2 estimates as demand for obesity and diabetes drugs fueled stronger earnings, prompting a raise in 2026 revenue guidance to $85–$87 billion. Q2 revenue was $22.97 billion with adjusted EPS of $8.38; Mounjaro worldwide sales reached $9.94 billion, Zepbound US sales were $4.93 billion, and Foundayo contributed $98 million in its first quarter of selling. International sales surged while price cuts trimmed some gains. The company highlighted ongoing aggressive M&A activity and expected benefits from Medicare coverage for obesity drugs.
Lilly reported Q2 2026 revenue of $23.0B, up 48% from a year earlier driven by Mounjaro and Zepbound, with GAAP EPS of $7.94 and non-GAAP EPS of $8.38; the company raised its full-year guidance to $85-87B in revenue and $35.50-$36.50 in non-GAAP EPS (midpoint up about $2.78) offset by $3.03 of acquired IPR&D charges, and highlighted regulatory wins (EBGLYSS for atopic dermatitis, Jaypirca in the EU for CLL) and continued obesity pipeline progress (retatrutide) with a planned BLA in 1Q 2027; Lilly also completed multiple acquisitions and announced additional investments to expand manufacturing in Indiana, underscoring a broad, growing pipeline.
Amy Schumer posted a series of unfiltered bikini photos on Instagram on Aug. 1, sharing her ongoing weight‑loss journey after more than a year on Mounjaro. She has previously discussed trying other weight‑loss drugs like Ozempic, undergoing liposuction, and addressing a Cushing syndrome diagnosis, noting she lost about 50 pounds—part of her broader, real‑talk discussion about body image and health.
Comedian Amy Schumer posted unfiltered Instagram photos from a yacht showing a dramatic weight loss (over 50 pounds) after starting Mounjaro to treat Cushing syndrome. The pictures feature her in a wetsuit, a floral bikini, and scuba diving, with supportive comments from friends; she has discussed divorce from Chris Fischer and has said the weight loss was not a cry for help.